HormoneIn Clinical Trials

CJC-1295

Subcutaneous injection

Overview

A synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from minutes to approximately 6-8 days.

Mechanism of Action

CJC-1295 stimulates pulsatile GH release from the anterior pituitary by binding to GHRH receptors while preserving the natural GH secretory pattern and negative feedback mechanisms..

Research Summary & Key Findings

Phase II clinical data showed sustained 2-3 fold increases in GH and IGF-1 levels for 6+ days after a single injection. Well-tolerated with dose-dependent effects on body composition parameters including lean mass gains.

Clinical Status

In Clinical Trials

CJC-1295 is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

Related Peptides in Hormone

Ipamorelin

In Clinical Trials

A highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...

View details

Sermorelin

FDA Approved

A synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...

View details

Tesamorelin (Egrifta)

FDA Approved

A synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...

View details

PT-141 (Bremelanotide / Vyleesi)

FDA Approved

A synthetic cyclic heptapeptide melanocortin receptor agonist that activates MC3R and MC4R in the central nervous system...

View details

Find a Provider

Find a verified provider who offers CJC-1295 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply CJC-1295.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.